• BRD4 Inhibition and Ferroptosis: Study Overview

  2026-10-11

  A source-grounded overview of a 2024 Discover Oncology study examining how BRD4 inhibition affects erastin-induced ferroptosis, with emphasis on reactive oxygen species, FSP1 regulation, evidence strength and limitations.

• Okadaic Acid Product Overview

  2026-10-09

  Okadaic acid (SKU A4540) is a marine-derived PP1 and PP2A inhibitor listed by APExBIO for conceptual research on phosphorylation-dependent signaling and apoptosis. No matched paper evidence is available here, so product performance and assay-specific applicability remain unvalidated.

• LY-411575: Reading Notch and Aβ Evidence Together

  2026-10-09

  LY-411575 is a potent gamma-secretase inhibitor for studying the shared biology of amyloid beta processing and Notch signaling. This article develops a causal framework linking biochemical potency to tumor-immune evidence while clarifying what the TNBC literature does—and does not—establish.

• Grazoprevir/Elbasvir: HCV Evidence Review

  2026-10-08

  The 2016 review by Vallet-Pichard and Pol explains the rationale for combining grazoprevir, an NS3/4A protease inhibitor, with elbasvir, an NS5A inhibitor, in interferon-free HCV therapy. Its evidence synthesis highlights high SVR rates, relevance to genotype 1 and 4 infection, and the importance of resistance, comorbidity, drug interactions, and changing treatment standards.

• SWI/SNF ATPases in H3.3K27M DIPG

  2026-10-07

  Mota and colleagues identified elevated SWI/SNF ATPase and PBAF-associated protein levels as a vulnerability in H3.3K27M diffuse intrinsic pontine glioma models. Their integrated genetic, pharmacologic, chromatin-accessibility, transcriptomic, and proteomic evidence links AU-15330-mediated degradation of SMARCA4, SMARCA2, and PBRM1 to reduced FOXO1-associated survival programs, while remaining limited to preclinical cellular systems.

• Antipyrine in BBB Permeability Research

  2026-10-07

  Antipyrine, also known as 1,5-dimethyl-2-phenylpyrazol-3-one, is a chemically defined analgesic and antipyretic research compound that may be relevant to pharmacokinetic studies and blood-brain barrier assessment. This overview examines its research context alongside a 2025 surrogate BBB model, separating published findings from interpretation and outlining limits on what the available evidence can support.

• Neomycin Sulfate: Mechanisms Across Biology

  2026-10-06

  Neomycin sulfate is an aminoglycoside antibiotic whose effects span RNA folding, DNA triplex stabilization, viral RNA–protein recognition, and ion-channel behavior. This article offers a cross-scale framework for interpreting those mechanisms alongside microbiome–immune research without confusing molecular probing with therapeutic evidence.

• Hydrocortisone in Biomedical Research: Evidence and Limits

  2026-10-06

  Hydrocortisone is an endogenous glucocorticoid hormone used as a reference compound for glucocorticoid receptor signaling, inflammation model research, and stress-response studies. Available evidence supports its value as a mechanistic probe, but the supplied prostate study concerns pleiotrophin rather than hydrocortisone, and commercial product descriptions should not be treated as equivalent to independently validated clinical or translational evidence.

• Solanesol Product Overview | APExBIO

  2026-10-05

  Solanesol is a supplier-described polyisoprenoid alcohol for research use. The available evidence is limited to product information, with no matched paper evidence provided to establish mechanisms, assay performance, or biological outcomes.

• EDI3 Inhibition in HER2-Therapy-Resistant Breast Cancer

  2026-10-05

  Keller et al. identify the glycerophosphodiesterase EDI3/GPCPD1 as a metabolically linked vulnerability in ER-HER2-positive breast cancer, including models resistant to HER2-targeted treatment. The study connects patient-tissue observations, signaling analysis, genetic perturbation, pharmacological inhibition, and tumor models, while supporting EDI3 as a preclinical target rather than an established clinical therapy.

• iPSC Cardiomyocytes for Chemical Hazard Prioritization

  2026-10-04

  Tsai and colleagues show that combining transcriptomic profiles with cardiomyocyte phenotypes can strengthen chemical hazard identification and risk characterization. Across 464 chemicals, the integrated framework connected functional effects, gene-expression changes, and exposure-informed points of departure while clarifying the limits of in vitro evidence.

• Partial BACE Inhibition and Synaptic Transmission

  2026-10-03

  Satir et al. show that moderate β-secretase inhibition can lower amyloid beta secretion by up to approximately 50% without measurable impairment of synaptic transmission in cultured primary rat neurons. The study’s key contribution is its parallel biochemical and functional assessment, while its in vitro design limits direct translation to clinical dosing or disease modification.

• Anti-Inflammatory, Anti-Angiogenic Airway Stents

  2026-10-02

  Zhao et al. developed an electrospun PAGL airway stent that combines anlotinib hydrochloride with silver nanoparticles to address infection, inflammation, angiogenesis, and fibroblast activation in tracheal in-stent restenosis. The rabbit and transcriptomic findings support a multifactorial stent-design strategy, while also highlighting the need for further work on safety, release behavior, and clinical translation.

• Difloxacin HCl: Applied Research Workflows

  2026-10-01

  Difloxacin HCl supports two distinct research paths: controlled antimicrobial susceptibility testing and exploratory multidrug resistance reversal studies. This workflow-centered guide connects DNA gyrase inhibition, MRP substrate sensitization, assay controls, and practical troubleshooting without confusing bacterial antibiotic activity with eukaryotic checkpoint biology.

• Myriocin: Mechanism, Evidence, and SPT Workflows

  2026-10-01

  Myriocin is a potent serine palmitoyltransferase inhibitor that blocks the initiating step of de novo sphingolipid biosynthesis. Its strongest research use is mechanistic control of sphingolipid metabolism, with reported activity in immunology and cancer research but assay-dependent cellular effects.

8661 records 1/578 page Next 12345 下5页 Last page